Cysteine and Glycine Supplements May Restore Glutathione and Fat Burning in Aging Muscle
A completed trial investigates whether replenishing glutathione precursors can reverse metabolic dysfunction in elderly adults.
Summary
As we age, levels of glutathione — the body's master antioxidant — decline in muscle tissue, while oxidative stress rises. This early-phase clinical trial investigated whether supplementing with glycine and cysteine (as N-acetylcysteine) could restore glutathione synthesis in skeletal muscle of older adults. Researchers also examined whether correcting this deficiency might improve fat oxidation in the fasted state, since elderly individuals are known to struggle with burning fat for fuel compared to younger adults. A secondary aim was to assess whether improved glutathione levels would correspond to reductions in total body fat. The trial used an isonitrogenous placebo (alanine) as a control and was sponsored by Rajagopal Sekhar at Baylor College of Medicine. Results from this completed study could point to a simple, low-cost nutritional strategy for combating age-related metabolic decline.
Detailed Summary
Oxidative stress is one of the most well-documented hallmarks of biological aging, and glutathione is the cell's primary defense against it. Yet despite its importance, elderly individuals are known to have significantly lower glutathione levels than younger adults — particularly in skeletal muscle. What has remained unclear is whether this deficit stems from reduced synthesis in muscle tissue itself, and whether it can be corrected through targeted nutritional intervention.
This completed early-phase clinical trial, led by Dr. Rajagopal Sekhar, set out to answer exactly that. The study tested whether supplementing with glycine and cysteine — the two rate-limiting precursors to glutathione biosynthesis — could meaningfully increase glutathione concentrations in aging skeletal muscle. Cysteine was delivered as N-acetylcysteine (NAC) for bioavailability, while alanine served as an isonitrogenous placebo control to isolate the specific effects of these precursors.
Beyond glutathione restoration, the trial examined whether this correction could improve mitochondrial function — specifically the ability to oxidize fat in the fasted state. Elderly adults characteristically burn less fat and more glucose when fasting, a metabolic inflexibility associated with obesity, insulin resistance, and accelerated aging. The study also tracked total body fat composition to see whether intracellular glutathione improvements translated to meaningful changes in fat storage.
The implications are significant. If glutathione deficiency is a root driver of impaired mitochondrial fat oxidation in aging, then glycine and NAC supplementation could offer a simple, affordable intervention to improve metabolic health in older populations — without requiring pharmacological agents.
Caveats are important here. This was an early-phase trial, likely small in sample size, and the full results are not publicly detailed in the available abstract. Generalizability and effect sizes remain unknown until the complete dataset is reviewed.
Key Findings
- Elderly adults have reduced glutathione synthesis in skeletal muscle, potentially addressable with glycine and NAC supplementation.
- Glycine and cysteine are rate-limiting glutathione precursors — supplying both may restore deficient levels in aging muscle.
- Impaired fat oxidation in fasted elderly adults may be linked to intracellular glutathione deficiency.
- Trial used an isonitrogenous alanine placebo, isolating the specific metabolic effects of glutathione precursors.
- Improved glutathione concentrations were hypothesized to associate with measurable reductions in total body fat.
Methodology
This was an early-phase (Phase 1) randomized controlled trial comparing glycine plus N-acetylcysteine supplementation against an isonitrogenous alanine placebo in elderly participants. Outcome measures included skeletal muscle glutathione synthesis, fasted-state fuel oxidation, and total body fat composition. The trial was sponsored by Rajagopal Sekhar and registered on ClinicalTrials.gov (NCT01870193).
Study Limitations
This summary is based on the abstract only, as the full study data are not publicly available — specific results, sample size, and effect sizes cannot be assessed. The trial was early-phase, suggesting it was primarily designed for feasibility and safety rather than definitive efficacy conclusions. Findings may not generalize across diverse elderly populations or different supplementation protocols.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.